These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38246843)

  • 1. Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
    Kumwichar P; Chongsuvivatwong V; Vasoppakarn S; Atthakul N; Nakhonsri V; Ngamphiw C; Khunkham P; Janpoung W; Tongsima S
    Vaccine; 2024 Feb; 42(4):844-852. PubMed ID: 38246843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
    Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
    JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
    Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
    PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Mallah SI; Alawadhi A; Jawad J; Wasif P; Alsaffar B; Alalawi E; Mohamed AM; Butler AE; Alalawi B; Qayed D; Almahari SA; Mubarak A; Mubarak A; Saeed S; Humaidan A; Kumar N; Atkin S; Alqahtani M
    Vaccine; 2023 Mar; 41(12):1925-1933. PubMed ID: 36725431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
    Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
    Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
    Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
    Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
    JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.
    Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH
    J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
    Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
    Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
    Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
    BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data.
    Kumwichar P; Poonsiri C; Botwright S; Sirichumroonwit N; Loharjun B; Thawillarp S; Cheewaruangroj N; Chokchaisiripakdee A; Teerawattananon Y; Chongsuvivatwong V
    JMIR Public Health Surveill; 2024 Mar; 10():e48255. PubMed ID: 38441923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
    Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
    BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multiprovincial retrospective analysis of the incidence of myocarditis or pericarditis after mRNA vaccination compared to the incidence after SARS-CoV-2 infection.
    Naveed Z; Chu C; Tadrous M; Veroniki AA; Li J; Rouleau I; Febriani Y; Calzavara A; Buchan SA; Nasreen S; Schwartz KL; Wilton J; Seo CY; Thampi N; Wilson SE; Naus M; De Serres G; Janjua NZ; Kwong JC;
    Heliyon; 2024 Mar; 10(5):e26551. PubMed ID: 38439866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand.
    Mahasing C; Doungngern P; Jaipong R; Nonmuti P; Chimmanee J; Wongsawat J; Boonyasirinant T; Wanlapakorn C; Leelapatana P; Yingchoncharoen T; Ngarmukos T; Chokephaibulkit K; Srimahachota S
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon.
    Moghnieh R; Mekdashi R; El-Hassan S; Abdallah D; Jisr T; Bader M; Jizi I; Sayegh MH; Rahman Bizri A
    Vaccine; 2021 Nov; 39(46):6713-6719. PubMed ID: 34656379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study.
    Hviid A; Nieminen TA; Pihlström N; Gunnes N; Dahl J; Karlstad Ø; Gulseth HL; Sundström A; Husby A; Hansen JV; Ljung R; Hovi P
    Eur Heart J; 2024 Apr; 45(15):1327-1335. PubMed ID: 38365960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
    Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ;
    J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.
    Matula Z; Gönczi M; Bekő G; Kádár B; Ajzner É; Uher F; Vályi-Nagy I
    Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.